Peposertib clinical trials
Also written M3814, MSC2490484A and Nedisertib.
How each study uses peposertib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the peposertib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2020 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 4 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 11
National Cancer Institute (NCI) (9) · EMD Serono Research & Development Institute, Inc. (4) · M.D. Anderson Cancer Center (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Merck KGaA, Darmstadt, Germany (1) · Gustave Roussy, Cancer Campus, Grand Paris (1)
Often tested with
Tested in the same studies.
Avelumab (3) · Temozolomide (2) · Lutetium Lu 177 dotatate (1) · Cisplatin (1) · Capecitabine (1) · Liposomal doxorubicin (1) · Doxorubicin (1) · Tuvusertib (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7
Studies that test peposertib.
- Dec 2026Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine TumorsPhase 1 · National Cancer Institute (NCI)
- Apr 2027Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal TherapyPhase 1/2 · National Cancer Institute (NCI)
- May 2027Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced SarcomaPhase 1 · National Cancer Institute (NCI)
- Jun 2027Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid LeukemiaPhase 1 · National Cancer Institute (NCI)
- Jul 2027Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary MalignanciesPhase 1/2 · National Cancer Institute (NCI)
- Aug 2027Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic CancerPhase 1/2 · National Cancer Institute (NCI)
- Aug 2027Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid TumorsPhase 1 · National Cancer Institute (NCI)
Studies
Open first, then newest update. How each study uses peposertib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced SarcomaRecruitingPhase 1National Cancer Institute (NCI)NCT05711615Written as Peposertib
- Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT05687136Written as Peposertib
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Peposertib
- Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary MalignanciesActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04068194Written as Peposertib
- Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03983824Written as Peposertib
- Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal TherapyActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04071236Written as Peposertib
- Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic CancerActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04172532Written as Peposertib
- Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine TumorsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04750954Written as Peposertib
- Effect of Food on Peposertib PKCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT04702698Written as Peposertib
- Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent GlioblastomaActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT04555577Written as Peposertib
- Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take CisplatinActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04533750Written as Peposertib
- A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04092270Written as Peposertib
- Study of Avelumab-M3814 CombinationsCompletedPhase 1EMD Serono Research & Development Institute, Inc.NCT03724890Written as M3814
- Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With RadiotherapyCompletedPhase 1EMD Serono Research & Development Institute, Inc.NCT02516813Written as M3814 100 mg
- Study of Peposertib in Combination With Capecitabine and RT in Rectal CancerCompletedPhase 1/2EMD Serono Research & Development Institute, Inc.NCT03770689Written as Peposertib 50 mg
- Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)TerminatedPhase 1EMD Serono Research & Development Institute, Inc.NCT03116971Written as M3814
- Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic LeukemiaCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT02316197Written as MSC2490484A (M3814)
What changed recently
From the registry's own updates since Oct 20, 2026.
Results posted1
- Effect of Food on Peposertib PKNov 6, 2026NCT04702698
Stopped1
Codes
What other systems call peposertib · ClinicalTrials.gg INT001600
- MeSH (NLM) C000716216peposertibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) GN429E725APEPOSERTIBConfirmed FDA, NLM
- NCI Thesaurus C120036PeposertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000716216 | peposertib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | GN429E725A | PEPOSERTIB | Confirmed FDA, NLM |
| NCI Thesaurus | C120036 | Peposertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.